Janus Kinase 1 Inhibition With Povorcitinib (INCB054707) in Hidradenitis Suppurativa: Efficacy and Safety During the Open-Label Extension Period of a Phase 2 Study

Joslyn S. Kirby, MD, MS, MEd,[1] Martin M. Okun, MD, PhD,[2] Afsaneh Alavi, MD,[3,4] Falk G. Bechara, MD,[5] Christos C. Zouboulis, MD, PhD,[3,6] Kurt Brown, MD,[7] Leandro L. Santos, MS,[7] Annie Wang, PhD,[7] Alexa B. Kimball, MD,[8] Martina L. Porter, MD[8]

[1]Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA; [2]Fort Memorial Hospital, Fort Atkinson, WI, USA; [3]European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany; [4]Mayo Clinic, Rochester, MN, USA; [5]Ruhr-University Bochum, Bochum, Germany; [6]Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany; [7]Incyte Corporation, Wilmington, DE, USA; [8]Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA

Presented at the 12th Conference of the European Hidradenitis Suppurativa Foundation (EHSF)
Florence, Italy • February 8–10, 2023
Session Name: Medical treatment: Place in therapy of systemic “historical” drugs and new advancements from clinical trials – Part 2
(Presentation S-0906; Abstract #258)

Background

- HS is a chronic inflammatory condition characterized by recurrent painful skin nodules and abscesses that can lead to draining tunnels, irreversible tissue damage, and scarring[1]
- Povorcitinib is an oral, small-molecule, selective JAK1 inhibitor
- Povorcitinib demonstrated dose-dependent efficacy in patients with HS in the 16-week randomized, placebo-controlled, phase 2 dose-ranging study conducted in North America and Europe[2–4]

Objective: To present efficacy and safety results for patients with HS treated with povorcitinib in the 36-week OLE period following the 16-week, randomized, placebo-controlled period

HS, hidradenitis suppurativa; JAK, Janus kinase; OLE, open-label extension.

1. Zouboulis CC, et al. *Dermatology*. 2015;231(2):184–190. **2.** Kirby JS, et al. P0004. Presented at: 31st European Academy of Dermatology and Venereology Congress (EADV); September 7–10, 2022; Milan, Italy and virtual. **3.** Kirby JS, et al. P0005. Presented at: 31st European Academy of Dermatology and Venereology Congress (EADV); September 7–10, 2022; Milan, Italy and virtual. **4.** Kirby JS, et al. P0006. Presented at: 31st European Academy of Dermatology and Venereology Congress (EADV); September 7–10, 2022; Milan, Italy and virtual.

Study Design (NCT04476043; EudraCT 2020-001981-13)



AN, abscess and inflammatory nodule; EOS, end of study; EOT, end of treatment; HiSCR, ≥50% reduction from baseline in AN count with no increase in the number of abscesses or draining tunnels (Hidradenitis Suppurativa Clinical Response); HiSCR75/90/100, ≥75%/90%/100% reduction from baseline in AN count with no increase in the number of abscesses or draining tunnels; IHS4-55/75/90/100, ≥55%/75%/90%/100% reduction from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) score; LTE, long-term extension; qd, once daily.

Patient Disposition



AE, adverse event.
* 2 patients were randomized but did not receive treatment.

Day 1 Baseline Demographic and Clinical Characteristics (OLE Population)

Characteristic	Total (N=174)	Placebo→75 mg (n=42)	15→75 mg (n=44)	45→75 mg (n=42)	75 mg (n=46)
Age, mean (SD), y	37.6 (11.2)	35.0 (9.8)	39.5 (10.8)	37.6 (12.7)	38.3 (11.0)
Women, n (%)	130 (74.7)	35 (83.3)	31 (70.5)	31 (73.8)	33 (71.7)
Race, n (%)					
White	120 (69.0)	31 (73.8)	32 (72.7)	26 (61.9)	31 (67.4)
Black/African-American	44 (25.3)	9 (21.4)	9 (20.5)	12 (28.6)	14 (30.4)
Other	10 (5.7)	2 (4.8)	3 (6.8)	4 (9.5)	1 (2.2)
HS duration, mean (SD), y	10.5 (9.6)	7.9 (6.6)	10.2 (8.5)	11.3 (12.1)	12.6 (10.1)
BMI, mean (SD), kg/m^2	35.4 (8.6)	33.8 (8.7)	35.4 (7.4)	36.4 (10.2)	35.8 (7.9)
Current or former smoker, n (%)	99 (56.9)	20 (47.6)	28 (63.6)	26 (61.9)	25 (54.3)
Hurley stage, n (%)					
I	14 (8.0)	4 (9.5)	3 (6.8)	4 (9.5)	3 (6.5)
II	122 (70.1)	28 (66.7)	34 (77.3)	29 (69.0)	31 (67.4)
III	38 (21.8)	10 (23.8)	7 (15.9)	9 (21.4)	12 (26.1)
Previous biologic treatment, n (%)	35 (20.1)	6 (14.3)	8 (18.2)	13 (31.0)	8 (17.4)
AN count, mean (SD)	11.2 (8.3)	10.6 (5.3)	11.3 (6.1)	12.6 (12.5)	10.5 (7.5)
Draining tunnel count, mean (SD)	2.2 (3.8)	2.5 (3.9)	2.0 (4.0)	2.5 (4.4)	1.8 (3.0)
IHS4 score, mean (SD)	21.7 (19.6)	22.1 (16.1)	20.8 (20.0)	24.3 (23.7)	19.7 (18.3)

BMI, body mass index.

AN Count and Percentage of Patients With ≥1 HS Flare (OLE Period)





- Mean (SD) change in AN count from Day 1 baseline at Week 52 was −5.7 (7.3), −8.4 (5.6), −10.4 (14.6), and −5.4 (5.6) in the placebo→75 mg, 15→75 mg, 45→75 mg, and 75 mg groups, respectively

* Defined as ≥25% increase from baseline in AN count with minimum increase of 2 AN.

HiSCR, HiSCR75, HiSCR90, HiSCR100 (OLE Period)



* Defined as ≥50%, ≥75%, ≥90%, and 100% reduction from baseline in AN count with no increase in the number of abscesses or draining tunnels.

IHS4-55, IHS4-75, IHS4-90, IHS4-100 (OLE Period)



- At Week 52, mean percentage change from Day 1 baseline in IHS4 in placebo→75 mg, 15→75 mg, 45→75 mg, and 75 mg groups was −52.8% (57.4), −67.7% (36.2), −72.5% (28.0), and −54.8% (49.5), respectively

* Defined as ≥55%, ≥75%, ≥90%, or ≥100% reduction from baseline in IHS4.

Safety (OLE Period)

Patients,* n (%)	Total (N=174)	Placebo→75 mg (n=42)	15→75 mg (n=44)	45→75 mg (n=42)	75 mg (n=46)
TEAE	133 (76.4)	32 (76.2)	34 (77.3)	35 (83.3)	32 (69.6)
SAE	9 (5.2)	1 (2.4)	3 (6.8)	1 (2.4)	4 (8.7)
Grade ≥3 TEAE	15 (8.6)	2 (4.8)	3 (6.8)	3 (7.1)	7 (15.2)
TEAE leading to discontinuation	6 (3.4)	0	3 (6.8)	0	3 (6.5)
Most common TEAEs					
COVID-19	37 (21.3)	8 (19.0)	8 (18.2)	9 (21.4)	12 (26.1)
Acne	20 (11.5)	8 (19.0)	4 (9.1)	4 (9.5)	4 (8.7)
Upper respiratory tract infection	19 (10.9)	4 (9.5)	5 (11.4)	5 (11.9)	5 (10.9)
Headache	10 (5.7)	3 (7.1)	5 (11.4)	1 (2.4)	1 (2.2)
Nasopharyngitis	10 (5.7)	2 (4.8)	5 (11.4)	3 (7.1)	0
Urinary tract infection	10 (5.7)	4 (9.5)	1 (2.3)	3 (7.1)	2 (4.3)
Blood CK increased	9 (5.2)	2 (4.8)	3 (6.8)	3 (7.1)	1 (2.2)
Select TEAEs					
Platelet count decreased	5 (2.9)	2 (4.8)	1 (2.3)	1 (2.4)	1 (2.2)
Anemia	3 (1.7)	0	1 (2.3)	0	2 (4.3)
Herpes zoster	3 (1.7)	0	1 (2.3)	0	2 (4.3)

CK, creatine phosphokinase; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
* Safety population included all patients who received ≥1 dose of study drug during the OLE.

Additional Safety (OLE Period)

- There were no fatal events
- 10 SAEs were reported in 9 patients and included myocardial infarction, congestive heart failure, infections (diverticulitis, perirectal abscess, sepsis), fall, diabetic ketoacidosis, ovarian cyst, pulmonary embolism, and HS
  - Congestive heart failure (45→75 mg); 59 y/o male, study Day 180 (OLE Day 61)
    - Risk factors included morbid obesity (BMI 65.4 kg/m^2), hypertension, coronary artery disease, hyperlipidemia, type 2 diabetes mellitus, stent (left anterior descending artery)
  - Myocardial infarction (75 mg); 42 y/o female, study Day 237 (OLE Day 148)
    - Risk factors included obesity (BMI 36.9 kg/m^2), high blood pressure, and hyperlipidemia
  - Pulmonary embolism (15→75 mg): 43 y/o male, study Day 167 (OLE Day 48)
    - Risk factors included obesity (BMI 38.4 kg/m^2), hypertension, active smoker, and bilateral knee sprains requiring immobilization for 1 month
- No SAEs in the OLE period were considered related to treatment by the investigator

Conclusions

- Results from the OLE of this phase 2 trial show that average efficacy improved for all treatment arms following the switch to povorcitinib 75 mg qd

- Clinical improvements observed with povorcitinib 75 mg qd during the OLE were durable, with responses observed among the strictest outcomes
  - HiSCR100 was achieved by 22% to 29% of patients
  - IHS4-100 was achieved by 20% to 29% of patients

- Povorcitinib 75 mg qd continued to be generally well tolerated through 52 weeks of treatment

- Recruitment is open in the phase 3 INCB 54707-301 study of povorcitinib versus placebo in patients with moderate-to-severe HS

Author Disclosures

- JSK has served as a speaker for AbbVie, Janssen, Novartis, and UCB; and as a consultant for AbbVie, Bayer, ChemoCentryx, Incyte Corporation, InflaRx, Insmed, Janssen, Novartis, Pfizer, and UCB
- MMO is a consultant for AbbVie, Azora, Bluefin, Boehringer Ingelheim, ChemoCentryx, Incyte, Innovaderm, InflaRx, Pfizer, and Vyne
- AA received honoraria as a consultant or advisory board participant from AbbVie, Novartis, Boehringer Ingelheim, and UCB; and received honoraria as an investigator for Boehringer Ingelheim and Processa
- FGB has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte, and Janssen-Cilag GmbH
- CCZ declares that none of the mentioned conflicts of interest had any influence on this abstract. He reports consultancy/advisory board disease-relevant honoraria from AbbVie, Bayer, Incyte, InflaRx, Janssen-Cilag, Novartis, Regeneron, and UCB. He has received speaker fees from AbbVie, Almirall, Biogen and UCB; is President of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV. He is Editor of the EADV News; is co-copyright holder of IHS4 on behalf of the EHSF e.V. His employer has received disease-relevant grants from AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB for his participation as clinical investigator
- KB, LLS, and AW are employees and shareholders of Incyte
- ABK is a consultant and investigator for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; investigator for AnaptysBio and Incyte; consultant for Bayer, Boehringer Ingelheim, Concert, EvoImmune, Moonlake, Sonoma Bio, and Ventyx; receives fellowship funding from AbbVie and Janssen; and serves on the Board of Directors for Almirall
- MLP is a consultant and/or investigator for AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, Novartis, Pfizer, Trifecta Clinical (in conjunction with Acelyrin, Moonlake, and Aristea), and UCB